Education
About Us
Working with TipRanks
Follow Us
Kodiak Sciences Inc (KOD)
NASDAQ:KOD
KOD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.92 - $16.30
Previous CloseN/A
Volume87.32K
Average Volume (3M)797.35K
Market Cap
$792.85M
Enterprise Value$257.91M
Total Cash (Recent Filing)$104.17M
Total Debt (Recent Filing)$65.21M
Price to Earnings (P/E)―
Beta3.41
Next Earnings
Nov 12, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding52,821,690
10 Day Avg. Volume1,012,341
30 Day Avg. Volume797,353
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue9.68
Enterprise Value/Gross Profit-2.63K
Enterprise Value/Ebitda-1.36
Forecast
1Y Price Target
$13.00Price Target Upside-16.07% Downside
Rating ConsensusHold
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Clinical TrialsOptimism on the KSI-101 opportunity in macular edema secondary to inflammation given encouraging ph.I APEX data showing 50% of patients gained 15+ letters BCVA and ~90% had no fluid.
Drug DevelopmentKOD has 3 drugs in ph.III for eye diseases, each with key readouts in 2026.
Vision GainsKSI-101 supported clinically meaningful BCVA vision gains and rapid retinal drying in macular edema secondary to inflammation patients.
Bears Say
Clinical ValidationReformulated conjugated tarcocimab and KSI-501 validation is not expected until 2026, leaving analysts awaiting pivotal confirmation.
Formulation DesignDe-risking of the enhanced formulation design remains critical due to former Phase 3 GLEAM and GLIMMER trial failures in diabetic macular edema and unexpected cataract adverse events over time for tarcocimab.
Market OpportunityKOD's tarcocimab is in GLOW2 ph.III for DR with data expected, but there is an expectation of limited market opportunity due to low VEGF use in NPDR patients without DME.
Kodiak Sciences News
KOD FAQ
What was Kodiak Sciences Inc’s price range in the past 12 months?
Kodiak Sciences Inc lowest stock price was $1.92 and its highest was $16.30 in the past 12 months.
What is Kodiak Sciences Inc’s market cap?
Kodiak Sciences Inc’s market cap is $792.85M.
When is Kodiak Sciences Inc’s upcoming earnings report date?
Kodiak Sciences Inc’s upcoming earnings report date is Nov 12, 2025 which is in 47 days.
How were Kodiak Sciences Inc’s earnings last quarter?
Kodiak Sciences Inc released its earnings results on Aug 13, 2025. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.068 by $0.038.
Is Kodiak Sciences Inc overvalued?
According to Wall Street analysts Kodiak Sciences Inc’s price is currently Overvalued.
Does Kodiak Sciences Inc pay dividends?
Kodiak Sciences Inc does not currently pay dividends.
What is Kodiak Sciences Inc’s EPS estimate?
Kodiak Sciences Inc’s EPS estimate is -1.02.
How many shares outstanding does Kodiak Sciences Inc have?
Kodiak Sciences Inc has 52,821,690 shares outstanding.
What happened to Kodiak Sciences Inc’s price movement after its last earnings report?
Kodiak Sciences Inc reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.068. Following the earnings report the stock price went up 16.473%.
Which hedge fund is a major shareholder of Kodiak Sciences Inc?
Currently, no hedge funds are holding shares in KOD
Kodiak Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.00 (-16.07% Downside)
$13.00 (-16.07% Downside)
Blogger Sentiment
Neutral
KOD Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 249.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
493.48%
12-Months-Change
Fundamentals
Return on Equity
-140.33%
Trailing 12-Months
Asset Growth
-36.07%
Trailing 12-Months
Company Description
Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
KOD Stock 12 Month Forecast
Average Price Target
$13.00
▼(-16.07% Downside)
Technical Analysis
Aldeyra Therapeutics
―
ADC Therapeutics
―
Greenwich LifeSciences
―
4D Molecular Therapeutics
―
Neumora Therapeutics, Inc.
―
Ownership Overview
34.72% Insiders
8.07% Mutual Funds
49.60% Other Institutional Investors
0.09% Public Companies and
Individual Investors